Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy

NCT01389583 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT01389583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01389583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2011
Completion date
October 31, 2019
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor